focus -WSS

focus

author：knowledge 2025-10-02 05:29:39 - browse：76

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Hilary may become 1st tropical storm to make landfall in California in 84 years

leisure time

WSS

Will biotech layoffs continue through 2023?

Interest rates are at a 22

Hilary expected to bring catastrophic, life

ActiGraph execs on goal of drug approvals with digital endpoints

Liz Cheney makes 1st public comment since Trump's election interference indictments

Alexander Hamilton and the argument for universal insurance

entertainment

focus

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

Behind warning on Apellis’s eye drug lies a conflict of interest

George Santos makes 1st court appearance after pleading not guilty to 13 counts

New details revealed about Purdue's marketing of OxyContin

Peter Hotez and the public health issue of online harassment

VC firm RA Capital starts a new synthetic biology incubator

Novavax promises a turnaround & Lilly roils the obesity market

Congress must give Medicare recipients genetic counseling access

The cancer drug shortage isn’t new — and neither are the solutions

Biden jokes that Republicans may impeach him because inflation is starting to cool down

leisure time

Alexander Hamilton and the argument for universal insurance

As the dark side of IVF slowly comes into focus, even more transparency is needed

Cancer drug shortages' outsize impact on ovarian cancer patients

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

Marc Tessier

New details revealed about Purdue's marketing of OxyContin

knowledge

focus

leisure time

Wikipedia